Gene:
ALX4
ALX homeobox 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  FPP; KIAA1788; PFM
PharmGKB Accession Id: PA24755

Details

Cytogenetic Location: chr11 : p11.2 - p11.2
GP mRNA Boundary: chr11 : 44282278 - 44331716
GP Gene Boundary: chr11 : 44279278 - 44341716
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to ALX4: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (New York, N.Y.). 2007. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007. Sladek Robert, et al. PubMed

LinkOuts

Entrez Gene:
60529
OMIM:
168500
605420
609597
613451
UCSC Genome Browser:
NM_021926
RefSeq RNA:
NM_021926
RefSeq Protein:
NP_068745
RefSeq DNA:
AC_000054
AC_000143
NC_000011
NG_015809
NT_009237
NW_001838022
NW_925006
UniProtKB:
ALX4_HUMAN (Q9H161)
Ensembl:
ENSG00000052850
GenAtlas:
ALX4
GeneCard:
ALX4
MutDB:
ALX4
ALFRED:
LO040051K
HuGE:
ALX4
Comparative Toxicogenomics Database:
60529
ModBase:
Q9H161
HumanCyc Gene:
HS00651
HGNC:
450

Common Searches